5-Methyl-1,3-benzenediacetonitrile

We are 5-Methyl-1,3-benzenediacetonitrile CAS:120511-74-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:5-Methyl-1,3-benzenediacetonitrile
CAS.NO:120511-74-2
Synonyms:5-Methyl-1,3-benzenediacetonitrile
5-METHYL-1,3-DIACETONITRILBENZENE
1,3-Benzenediacetonitrile,5-methyl
1-METHYL-3,5 BENZENE DIACETONITRILE
5-Methyl-1,3-diacetonitrilbezene
 
Physical and Chemical Properties:
Density 1.1±0.1 g/cm3
Boiling Point 342.0±32.0 °C at 760 mmHg
Melting Point 71-72°C
Molecular Formula C11H10N2
Molecular Weight 170.210
Flash Point 164.5±19.0 °C
 
Specification:
Appearance:Off-white crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Anastrozole(CAS:120511-73-1).

5-Methyl-1,3-benzenediacetonitrile


Related News: The downstream industry of the pharmaceutical intermediate industry is mainly the production of APIs, and the relationship between APIs and preparations is in the upstream and downstream industry chain. The consumer demand for downstream preparations will directly affect the demand for APIs.4-(orthodimethylphosphinylanilino)-5-chloro-2-chloropyrimidine CAS:1197953-49-3 This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved.rac-1- (4-fluorofenil) -1,3-dihidroisobenzofuran-5-carbonitrilo CAS:64169-67-1 This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved.5-amino-1- (N-metilcarbamoil) imidazol-4-carboxamida CAS:188612-53-5 Fate Therapeutics has exclusively licensed from MSK foundational intellectual property covering the production and composition of iPSC-derived T cells.Fate Therapeutics has exclusively licensed from MSK foundational intellectual property covering the production and composition of iPSC-derived T cells.

Related Products
Product Name
3-Morpholino-5,6-dihydropyridin-2(1H)-one View Details
cumene View Details
2-(Chloromethyl)-3,4-dimethoxypyridine Hydrochloride View Details
Isopropyl 2-(3-Nitrobenzylidene)acetoacetate manufacturer (Oxydi-2,1-phenylene)bis(diphenylphosphine) manufacturer 4-Chloro-3-fluorobenzaldehyde manufacturer (R,E)-5-([1,1′-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpent-2-enoic acid manufacturer (9-(naphthalen-1-yl)-9H-carbazol-3-yl)boronic acid manufacturer